trending Market Intelligence /marketintelligence/en/news-insights/trending/CWdxbd8rgC59zJ0Q-OE01g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cancer drug developer Revolution Medicines plans $100M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cancer drug developer Revolution Medicines plans $100M IPO

Revolution Medicines Inc. is planning an IPO of up to $100 million of its common stock on the Nasdaq Global Market.

The Redwood City, Calif.-based pharmaceutical company develops medicines for cancer patients by translating frontier oncology targets — proteins that drive the growth of cancers or that control immune responses that can defeat them.

Revolution Medicines plans to list on the Nasdaq Global Market under the ticker symbol RVMD.

The company — led by director, President and CEO Mark Goldsmith — plans to use the net proceeds from the IPO to fund various studies and the development of its potential drug candidates. A part of the proceeds might also be used for hiring additional personnel, capital expenditures and the cost of operating as a public company.

Revolution's RMC-4630 is being evaluated in an early-stage monotherapy clinical study for the treatment of a range of tumor types.

Asset management companies Third Rock Ventures LLC and The Column Group LLC own 28.8% and an 18.6% stake in the company, respectively.

J.P. Morgan Securities LLC, Cowen and Co. LLC, SVB Leerink LLC and Guggenheim Securities LLC are serving as the book-running managers for the offering.